Amalgamated Bank Has $3.37 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Amalgamated Bank reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 11.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,017 shares of the biotechnology company’s stock after selling 18,465 shares during the period. Amalgamated Bank’s holdings in Exelixis were worth $3,371,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of EXEL. Fisher Asset Management LLC grew its position in Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 728 shares in the last quarter. Rise Advisors LLC bought a new position in shares of Exelixis in the 1st quarter valued at about $28,000. Park Place Capital Corp acquired a new stake in shares of Exelixis in the second quarter valued at about $45,000. GAMMA Investing LLC raised its holdings in Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC raised its holdings in Exelixis by 537.2% during the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,746 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Insider Transactions at Exelixis

In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now directly owns 721,680 shares in the company, valued at $19,622,479.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Dana Aftab sold 95,000 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now directly owns 520,990 shares in the company, valued at $13,024,750. The disclosure for this sale can be found here. In the last 90 days, insiders sold 302,858 shares of company stock valued at $7,980,629. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

Shares of Exelixis stock opened at $26.36 on Tuesday. The firm has a 50-day moving average of $25.28 and a 200-day moving average of $23.38. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $27.83. The stock has a market cap of $7.99 billion, a PE ratio of 41.19, a PEG ratio of 0.58 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. The firm had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. Equities research analysts predict that Exelixis, Inc. will post 1.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Truist Financial reiterated a “buy” rating and issued a $33.00 price target (up previously from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. Royal Bank of Canada restated an “outperform” rating and set a $27.00 price objective on shares of Exelixis in a research note on Wednesday, August 7th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.